ExpressPoints Melanoma: Expert Guidance and Resources to Optimize Care Along the Treatment Continuum

Part 2 of KEYNOTE-054 trial of adjuvant pembrolizumab vs placebo in high-risk stage III melanoma from ASCO 2021 as reported by Clinical Care Options (CCO)

5-year update of the COLUMBUS trial of encorafenib + binimetinib in BRAF V600-mutant melanoma from ASCO 2021 as reported by Clinical Care Options (CCO)

ABC study of nivolumab plus ipilimumab update at 5 years in patients with melanoma brain metastases from ASCO 2021 as reported by Clinical Care Options (CCO)

LEAP 004 trial update on lenvatinib + pembrolizumab in patients with advanced melanoma and progression on anti-PD-1/PD-L1 therapy from ASCO 2021 reported by Clinical Care Options (CCO)